Todos os estudos
RecrutamentoExploratório terapêutico (Fase II)Intervencionista

An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Primary Sclerosing Cholangitis (PSC)

This study is looking at a new medicine called A3907 for adults who have a liver condition called Primary Sclerosing Cholangitis, or PSC. It's a 'Phase 2' study, which means it's still in the early stages of testing. The main goal is to check how safe A3907 is and whether people can take it for 12 weeks without experiencing too many side effects. Researchers will also look at how the body handles the medicine and how it might affect numbers related to PSC, like certain liver tests. This research is important to understand if A3907 could be a helpful treatment in the future.

Em resumo

Status
Recrutamento
Fase
Exploratório terapêutico (Fase II)
Patrocinador
Albireo AB, Albireo AB
Meta de inscrição
26
Iniciar
15 Dez 2022

Sobre o que é este estudo?

This study is focusing on a condition called Primary Sclerosing Cholangitis, often shortened to PSC. PSC is a long-term liver disease that slowly damages the bile ducts, which are tubes that carry digestive fluid from the liver. There's currently no cure for PSC, so researchers are always looking for new ways to help manage it and improve patients' health.

Here, they are testing a new medicine called A3907. This is a 'Phase 2' study, meaning it's an early step in checking if a new medicine works and is safe. The top priority for the researchers is to understand if A3907 is safe for people to take and if they can tolerate it well over 12 weeks. This includes watching out for any unwanted side effects that might happen.

Beyond safety, the study also wants to learn how the body uses and gets rid of the medicine. They will also measure how A3907 affects certain substances in your blood and urine, including things related to how your liver is working. This information will help doctors understand if A3907 might be a good option for treating PSC in the future.

Pontos principais

  • This study is testing a new medicine (A3907) for PSC.
  • The main goal is to check its safety and if people can tolerate it.
  • It's an early-stage (Phase 2) clinical trial.
  • Participation involves taking the medicine and having regular check-ups for 12 weeks.
  • Adults aged 18 and over with PSC can be considered.

Quem pode ser elegível?

To join this study, participants must be at least 18 years old. Both men and women can take part.

There will be other specific health requirements that aren't listed here. For example, you might need to have a confirmed diagnosis of PSC and your liver condition might need to be at a certain stage.

It's very important to discuss your full medical history with the study doctors to see if you meet all the criteria to safely participate.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Do you have a diagnosis of Primary Sclerosing Cholangitis (PSC)?
  3. Are you able to attend regular clinic visits for 12 weeks?
  4. Are you willing to take a new experimental medicine?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you would primarily be taking the new medicine, A3907, for 12 weeks. During this time, you would have regular visits to the study clinic. These visits would likely involve taking blood and urine samples so doctors can check how your body is reacting to the medicine and monitor your liver function. They will also ask you questions about how you are feeling and if you are experiencing any side effects. The total length of your participation, including follow-up, would be discussed with you.

Riscos e benefícios potenciais

Potential benefits of taking part include contributing to medical research that could help others with PSC and potentially seeing an improvement in your own condition from the new medicine. However, there's no guarantee the medicine will help you, and you might experience side effects, some of which could be serious. All potential risks will be thoroughly explained before you decide to join. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Localizações (4)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Espanha
  • —
    Não verificado
    Itália
  • —
    Não verificado
    França
  • —
    Não verificado
    Polônia

Perguntas frequentes

What is Primary Sclerosing Cholangitis (PSC)?

PSC is a long-term liver disease that damages the small tubes (bile ducts) in your liver, which can lead to liver problems over time.

What is A3907?

A3907 is a new medicine being tested in this study to see if it can help people with PSC. It's not yet approved for general use.

What does 'Phase 2 study' mean?

Phase 2 means it's an early research stage where doctors check if a new medicine is safe and if it shows any signs of working.

What are 'side effects'?

Side effects are any unwanted or unexpected reactions you might have to a medicine. The study will carefully record these.

Will I definitely get the new medicine?

In some 'Phase 2' studies, everyone gets the new medicine, but sometimes there's a comparison group. You should ask the study team about this.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "An Open Label, Phase 2 Study to Evaluate the Effect of A3907…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.